ISSN: 2376-127X

Журнал беременности и здоровья детей

Открытый доступ

Наша группа организует более 3000 глобальных конференций Ежегодные мероприятия в США, Европе и США. Азия при поддержке еще 1000 научных обществ и публикует более 700 Открытого доступа Журналы, в которых представлены более 50 000 выдающихся деятелей, авторитетных учёных, входящих в редколлегии.

 

Журналы открытого доступа набирают больше читателей и цитируемости
700 журналов и 15 000 000 читателей Каждый журнал получает более 25 000 читателей

Индексировано в
  • Индекс Коперника
  • Google Scholar
  • Академические ключи
  • РефСик
  • Университет Хамдарда
  • ЭБСКО, Аризона
  • OCLC- WorldCat
  • Публикации
  • Женевский фонд медицинского образования и исследований
  • Евро Паб
  • ICMJE
Поделиться этой страницей

Абстрактный

Effect of Ferric Sodium EDTA in Combination with Vitamin C, Folic Acid, Copper, Zinc, and Selenium, for Prevention of Iron Deficiency Anemia during Pregnancy

Claudia Guaraldi, Demetrio Costantino, Annalisa Curcio, Fabiana Nano, Adriana Romano, Michele Pironti

During pregnancy iron requirement increases for meet the needs of mother and fetus development and growth. Often iron stores of pregnant women are not sufficient, inducing a major risk of occurrence of iron deficiency (ID) and iron deficiency anemia (IDA), that have been associated with major risk of adverse pregnancy outcomes. The aim of this study was to verify the effect of the administration of 1 tablet a day of Ferric Sodium EDTA in combination with vitamin C, folic acid, copper gluconate, zinc gluconate and selenomethionine (Ferachel Forte®), on the hematological status of pregnant women, with reference to the prevention of IDA in pregnancy. Pregnant non-anemic women (N=100) were enrolled and randomized to treatment with Ferric Sodium EDTA combination (Group A, N=50) or with folic acid (Group B, N=50). Blood parameters of hemoglobin (Hb), total number of red blood cells (RBCs), ferritin, and transferrin were evaluated at T0: before starting therapy (<12th week), T1 at 20-24 weeks, T2 at 30-32 weeks, and T3 at 36 weeks. Degree of tolerability in treatment group and adverse events eventually reported were added as evaluation of safety. Results showed that Group A maintained almost unchanged blood parameters evaluated and the therapy was effective to prevent IDA on A. Group B results showed a worsening statistically significant (P < 0.001) of all parameters evaluated. In Group a most women reported that treatment was safe and well tolerated. In conclusion, this study confirmed the efficacy and safety of supplementation with Ferric Sodium EDTA in combination with vitamin C, folic acid, copper gluconate, zinc gluconate, and selenomethionine (Ferachel Forte®), for preventing anemia in pregnant women.